TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38012285
Drug: gosuranemab low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: gosuranemab low-dose (125 mg q4w)
Study: 38012285
Drug: gosuranemab intermediate-dose
Normalized name: Prevotella intermedia
Approvals — FDA: no, EMA: no, PMDA: no
Description: gosuranemab intermediate-dose (600 mg q4w)
Study: 38012285
Drug: gosuranemab high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: gosuranemab high-dose (2000 mg q4w)
Study: 38012285
Drug: gosuranemab (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: gosuranemab (all doses)
Study: 38012450
Drug: Device-encapsulated pancreatic
Normalized name: Pancreatin
DrugBank: Pancrelipase (DB00085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Device-encapsulated pancreatic precursor cells derived from human embryonic stem cells, 2-3-fold higher cell doses, optimized membrane perforation pattern.
Study: 38012450
Drug: Continuous glucose
Normalized name: sub-q infusion pump w/continuous glucose monitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous glucose monitoring (CGM) and insulin dosing.
Study: 38012534
Drug: Sotatercept (starting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sotatercept (starting dose 0.3 mg/kg; target dose 0.7 mg/kg)
Study: 38012682
Drug: Decitabine and
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Decitabine and ATRA (all-trans retinoic acid) combination therapy administered over 52 cycles
Study: 38012795
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of amisulpride (100 mg)
Study: 38012835
Drug: Pegfilgrastim 7.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegfilgrastim 7.2 mg
Study: 38013135
Drug: Completely oral
Normalized name: Canker Complete Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Completely oral anticoagulation
Study: 38013135
Drug: Sequential anticoagulation
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential anticoagulation with DOACs
Study: 38013135
Drug: Sequential anticoagulation
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential anticoagulation with VKAs
Study: 38013135
Drug: Completely parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Completely parenteral anticoagulation
Study: 38013594
Drug: 4CMenB and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4CMenB and MenACWY vaccines (two doses, given 1 month apart)
Study: 38014462
Drug: Brief Observable
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brief Observable Anxiety Sensitivity Treatment (BOAST) - a single clinician-led intervention session followed by a two-week ecological momentary intervention (EMI) via mobile app.
Study: 38014691
Drug: High autoantibody
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High autoantibody concentrations targeting complement factor C3a receptor
Study: 38014691
Drug: High autoantibody
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High autoantibody concentrations targeting vascular endothelial growth factor receptor-2
Study: 38015220
Drug: Toripalimab (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toripalimab (240 mg) plus gemcitabine-cisplatin
Study: 38015366
Drug: Elosan Cabin
Normalized name: Pogostemon cablin top extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elosan Cabin C1 treatment (8 sessions over 9 weeks)
Study: 38015467
Drug: Lenalidomide 15
Normalized name: lenalidomide 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenalidomide 15 mg
Study: 38015598
Drug: Smartwatch-smartphone dyad
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smartwatch-smartphone dyad for AF detection (Pulsewatch system) plus an electrocardiogram patch
Study: 38015598
Drug: Electrocardiogram patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrocardiogram patch alone
Study: 38015877
Drug: Nonoperative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonoperative treatment (control)
Study: 38016021
Drug: BNT162b2-Omi.BA.4/BA.5 (30-µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: BNT162b2-Omi.BA.4/BA.5 (30-µg second booster)
Study: 38016160
Drug: TB-ART treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: TB-ART treatment
Study: 38016322
Drug: Adjuvanted protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvanted protein vaccine (5, 15 or 45 μg)
Study: 38016322
Drug: mRNA vaccine
Normalized name: RSV mRNA vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: mRNA vaccine (10, 20, or 50 μg)
Study: 38016482
Drug: Pucotenlimab at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pucotenlimab at 200 mg every 3 weeks
Study: 38016718
Drug: Intravenous trastuzumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous trastuzumab (arm A)
Study: 38016718
Drug: Subcutaneous trastuzumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous trastuzumab (arm B)
Study: 38016950
Drug: Nicotinamide riboside
Normalized name: Nicotinamide riboside
DrugBank: Nicotinamide riboside (DB14933)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotinamide riboside (NR) 1500 mg twice daily
Study: 38017325
Drug: EMI-137 (0.09
Approvals — FDA: no, EMA: no, PMDA: no
Description: EMI-137 (0.09 mg/kg, 0.13 mg/kg, 0.18 mg/kg)
Study: 38017432
Drug: High levels
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High levels of IL-6 (≥9.5 pg/mL)
Study: 38017500
Drug: Hydrolyzed collagen
Normalized name: Preprotein Hydrolyzed Collagen Liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrolyzed collagen (10 g) and vitamin C (40 mg) supplementation for 24 weeks combined with progressive tendon loading exercises (PTLE)
Study: 38017500
Drug: Placebo (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (10 g maltodextrin) combined with progressive tendon loading exercises (PTLE)
Study: 38017574
Drug: ReSeT intervention
Normalized name: Rest Simply
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ReSeT intervention (online psychoeducational program and video therapy sessions)
Study: 38017663
Drug: Perampanel as
Normalized name: Perampanel
DrugBank: Perampanel (DB08883)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Perampanel as add-on therapy
Study: 38017663
Drug: Perampanel as
Normalized name: Perampanel
DrugBank: Perampanel (DB08883)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Perampanel as substitution therapy
Study: 38018158
Drug: Daily egg
Normalized name: EGG
DrugBank: Egg (DB10529)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily egg consumption for six months
Study: 38018460
Drug: Tislelizumab (anti-PD-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tislelizumab (anti-PD-1 antibody) added to radiation therapy
Study: 38018840
Drug: IVUS-guided treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVUS-guided treatment decision
Study: 38018840
Drug: FFR-guided treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: FFR-guided treatment decision
Study: 38019116
Drug: Giredestrant 30
Normalized name: Giredestrant
DrugBank: Giredestrant (DB19125)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Giredestrant 30 mg once daily
Study: 38019116
Drug: Giredestrant 90
Normalized name: Giredestrant
DrugBank: Giredestrant (DB19125)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Giredestrant 90 mg once daily
Study: 38019116
Drug: Giredestrant 100
Normalized name: Giredestrant
DrugBank: Giredestrant (DB19125)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Giredestrant 100 mg combined with palbociclib 125 mg
Study: 38019116
Drug: Giredestrant 10,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Giredestrant 10, 30, 90, or 250 mg once daily (dose-escalation stage)
Study: 38019116
Drug: Giredestrant 30,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Giredestrant 30, 100, and 250 mg once daily (dose-expansion stage)
Study: 38019356
Drug: BI 1358894
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 1358894 100 mg
Study: 38019444
Drug: Metronomic oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronomic oral cyclophosphamide and methotrexate (CM) combined with bevacizumab (Arm A)
Study: 38019444
Drug: Metronomic oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronomic oral cyclophosphamide and methotrexate (CM) alone (Arm B)
Study: 38019467
Drug: Parent-led, telehealth-delivered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parent-led, telehealth-delivered cognitive behavioral therapy (CBT) program
Study: 38019571
Drug: Sleep Treatment
Normalized name: Sleep
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sleep Treatment Education Program for Young Adult Cancer Survivors (STEP-YA)
Study: 38019593
Drug: Acceptance and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acceptance and Mindfulness-Based Exposure Therapy
Study: 38019656
Drug: SARS-CoV-2 vaccines
Approvals — FDA: no, EMA: no, PMDA: no
Description: SARS-CoV-2 vaccines (third doses)
Study: 38019657
Drug: Tenofovir rectal
Normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tenofovir rectal douche 220 mg iso-osmolar product A
Study: 38019657
Drug: Tenofovir rectal
Normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tenofovir rectal douche 660 mg iso-osmolar product B
Study: 38019657
Drug: Tenofovir rectal
Normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tenofovir rectal douche 660 mg hypo-osmolar product C
Study: 38019901
Drug: Filgotinib 200
Normalized name: nilotinib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Filgotinib 200 mg with concomitant immunomodulator (IM)
Study: 38019956
Drug: Bacillus Calmette-Guérin
Normalized name: Bacillus Calmette-Guérin (BCG) vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bacillus Calmette-Guérin (BCG) injection of 2 × 106 to 16 × 106 colony-forming units
Study: 38019956
Drug: Bacillus Calmette-Guérin
Normalized name: Bacillus Calmette-Guérin (BCG) vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bacillus Calmette-Guérin (BCG) injection
Study: 38020288
Drug: Berotralstat (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Berotralstat (150 mg daily)
Study: 38021251
Drug: Rumination-focused cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rumination-focused cognitive behavioral therapy (RF-CBT)
Study: 38021297
Drug: Amnion collagen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amnion collagen matrix wrap and bone marrow aspirate concentrate (BMAC) injection during graft preparation.
Study: 38021373
Drug: Consecutive-day group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Consecutive-day group (daily 100 mg iron for 90 d, followed by daily placebo for another 90 d)
Study: 38021373
Drug: Alternate-day group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternate-day group (same daily dose of iron and placebo on alternate days for 180 d)
Study: 38023544
Drug: mRNA-1273 vaccine
Normalized name: SARS-CoV-2 mRNA-1273 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: mRNA-1273 vaccine (2 doses at months 0 and 1)
Study: 38023544
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care (receipt of COVID-19 vaccine)
Study: 38023545
Drug: Better WASH
Normalized name: Zencia Wash
DrugBank: Octasulfur (DB09353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Better WASH households (defined by safe source of water for daily use, safe source of drinking water, private/shared flush toilet use, and always handwashing with soap after defecation)
Study: 38023553
Drug: Dolutegravir (DTG;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dolutegravir (DTG; 50 mg once per day) plus Darunavir boosted with cobicistat (DRV/c; 800/150 mg once per day)
Study: 38023556
Drug: Direct-acting antiviral
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct-acting antiviral treatments for HCV
Study: 38023564
Drug: Third SARS-CoV-2
Normalized name: SARS-CoV-2 Sclamp
DrugBank: SARS-CoV-2 Sclamp (DB15849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Third SARS-CoV-2 vaccine (mRNA-1273 or BNT162b2)
Study: 38023564
Drug: Basic immunization
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic immunization (first and second vaccines)
Study: 38024244
Drug: Cediranib (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cediranib (20 mg) in combination with radiation and temozolomide
Study: 38024244
Drug: Placebo in
Normalized name: placebo INTRAVEN VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo in combination with radiation and temozolomide
Study: 38025217
Drug: Drug-induced acute
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-induced acute kidney injury (DI-AKI) cases
Study: 38025217
Drug: Nephrotoxic drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nephrotoxic drugs (e.g., vancomycin, NSAIDs, piperacillin/tazobactam)
Study: 38025806
Drug: Concurrent chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemoradiotherapy for stage IIIA (30.2%) and stage IIIB (37.0%) patients
Study: 38027106
Drug: Exenatide 2
Normalized name: exenatide 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exenatide 2 mg weekly injections
Study: 38027419
Drug: 0.2-μg/day fluocinolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2-μg/day fluocinolone acetonide implant (FAi)
Study: 38027469
Drug: Oral Ambroxol
Normalized name: ambroxol
DrugBank: Ambroxol (DB06742)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Ambroxol (ABX) 1.2 g/day
Study: 38028146
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone (40.4%)
Study: 38028146
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus surgery (33.8%)
Study: 38028146
Drug: Sequential chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential chemoradiotherapy (CRT) (17.6%)
Study: 38028146
Drug: Concurrent CRT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent CRT (9.3%)
Study: 38028272
Drug: transcutaneous spinal
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: transcutaneous spinal stimulation-enhanced walking therapy (WALK)
Study: 38028429
Drug: Remote electrical
Normalized name: remote electrical neuromodulation (REN) device
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remote electrical neuromodulation (REN) device used for acute treatment of migraine, applied for 45 minutes, used on at least 10 days every 28-day month
Study: 38028977
Drug: Internet-based cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based cognitive-behavioral therapy (9 sessions)
Study: 38028985
Drug: EBV-positive diffuse
Normalized name: Oldenlandia diffusa extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: EBV-positive diffuse large B-cell lymphoma treatment
Study: 38028985
Drug: EBV-positive classic
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EBV-positive classic Hodgkin lymphoma treatment
Study: 38029356
Drug: Recombinant erythropoietin
Normalized name: RECOMBINANT HUMAN ERYTHROPOIETIN ALFA
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant erythropoietin (rEPO) - Epoetin alpha 40,000 international units per week administered subcutaneously until hemoglobin (Hb) >11 g/dL and then tapered off.
Study: 38029357
Drug: Fol-CHOP (pralatrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fol-CHOP (pralatrexate 30 mg/m2 combined with CHOP)
Study: 38029807
Drug: p75NTR inhibitor
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: p75NTR inhibitor LM11A-31
Study: 38029831
Drug: Previous immune
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Previous immune checkpoint inhibitor therapy (ICI)
Study: 38030258
Drug: 4 g EPA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g EPA ethyl ester (icosapent ethyl (IPE; Vascepa)) daily
Study: 38030303
Drug: NIS793 plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: NIS793 plus spartalizumab (NIS793 0.3-30 mg/kg Q3W and spartalizumab 300 mg Q3W or NIS793 20-30 mg/kg Q2W and spartalizumab 400 mg Q4W)
Study: 38030303
Drug: NIS793 monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NIS793 monotherapy (0.3-1 mg/kg every 3 weeks)
Study: 38030303
Drug: NIS793 plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: NIS793 plus spartalizumab (at recommended dose for expansion)
Study: 38030319
Drug: Darbepoetin alfa
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Darbepoetin alfa (10 μg/kg subcutaneously once a week for 8 weeks)
Study: 38030962
Drug: Prophylactic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic treatment (76.2% of participants)
Study: 38031088
Drug: Schedule-I group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Schedule-I group (3 DC injections with 28-day interval)
Study: 38031088
Drug: Schedule-II group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Schedule-II group (3 DC injections with 7-day interval for first course, then 28-day interval)
Study: 38031584
Drug: 12 weeks
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12 weeks of cognitive-behavioral therapy (CBT)
Study: 38031584
Drug: 24 weeks
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 24 weeks of cognitive-behavioral therapy (CBT)
Study: 38032573
Drug: Aficamten in
Normalized name: Aficamten
DrugBank: Aficamten (DB18490)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aficamten in addition to standard-of-care medications
Study: 38032573
Drug: Placebo in
Normalized name: placebo INTRAVEN VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo in addition to standard-of-care medications
Study: 38032624
Drug: Active hypoglossal
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active hypoglossal nerve stimulation (HGNS) therapy
Study: 38032624
Drug: Sham hypoglossal
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham hypoglossal nerve stimulation (HGNS) therapy
Study: 38033143
Drug: Treatment goals
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment goals
Study: 38033284
Drug: Bosutinib 400
Normalized name: bosutinib 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bosutinib 400 mg/m
Study: 38033284
Drug: Bosutinib 300
Normalized name: Bosutinib
DrugBank: Bosutinib (DB06616)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Bosutinib 300 mg/m
Study: 38033284
Drug: Bosutinib 350
Normalized name: Bosutinib
DrugBank: Bosutinib (DB06616)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Bosutinib 350 mg/m
Study: 38033375
Drug: tablet-based serious
Normalized name: clotrimazole
DrugBank: Clotrimazole (DB00257)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tablet-based serious game therapy (SGT), 4 months, four 20-min sessions/week
Study: 38033459
Drug: Oral cannabidiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cannabidiol 600 mg/d
Study: 38034010
Drug: Mediterranean (MED)
Normalized name: Thynnus mediterraneus flesh
DrugBank: Northern bluefin tuna (DB14162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mediterranean (MED) diet (hypocaloric, lower in carbohydrates, includes walnuts 28 g/day)
Study: 38035363
Drug: 15 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 g specific collagen peptides (SCP)
Study: 38035747
Drug: Icatibant (bradykinin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Icatibant (bradykinin inhibitor)
Study: 38036487
Drug: Valganciclovir (dose-adjusted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valganciclovir (dose-adjusted for renal clearance)
Study: 38036712
Drug: Entinostat 8
Normalized name: entinostat
DrugBank: Entinostat (DB11841)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Entinostat 8 mg PO days 1 and 15 + Pembrolizumab 200 mg IV day 1 every 21 days
Study: 38036720
Drug: Eftozanermin alfa
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eftozanermin alfa monotherapy 2.5-15 mg/kg on Day 1 or Days 1/8 of a 21-day cycle
Study: 38036720
Drug: Eftozanermin alfa
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eftozanermin alfa monotherapy or combination therapy with oral venetoclax 400-800 mg daily (1.25-7.5 mg/kg Days 1/8/15 of a 21-day cycle)
Study: 38036720
Drug: Eftozanermin alfa
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eftozanermin alfa (3.75 or 7.5 mg/kg Days 1/8/15/22 of a 28-day cycle) and FOLFIRI regimen with/without bevacizumab
Study: 38036761
Drug: Bifidobacterium breve
Normalized name: Bifidobacterium Breve
DrugBank: Bifidobacterium breve (DB16549)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bifidobacterium breve Bif195 (≥10 billion CFU) co-administered with aspirin 300 mg daily for 4 weeks
Study: 38036946
Drug: Ustekinumab (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ustekinumab (6 mg/kg IV at Week 0, 90 mg SC at Week 8)
Study: 38037105
Drug: mHealth using
Approvals — FDA: no, EMA: no, PMDA: no
Description: mHealth using cellular-enabled electronic dose monitoring
Study: 38037108
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg of CBD
Study: 38037749
Drug: Occupational therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occupational therapy lifestyle intervention
Study: 38037839
Drug: HS-10352 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HS-10352 at 6 mg QD
Study: 38037839
Drug: HS-10352 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HS-10352 at 8 mg QD
Study: 38037839
Drug: HS-10352 (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: HS-10352 (all doses)
Study: 38038866
Drug: Ad5-nCoV vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ad5-nCoV vaccine booster dose
Study: 38039427
Drug: Canakinumab (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canakinumab (200 mg subcutaneously once every 3 weeks)